Skip to main content
. 2018 Jun 27;8:9743. doi: 10.1038/s41598-018-28066-w

Figure 1.

Figure 1

Biomarker discovery scheme. (a) Input matrices are multi-dimensional pharmacological, genomic, transcriptomic, and tumour-type data aligned by cell lines. (b) The joint non-negative matrix factorization (JNMF) method detects multi-dimensional co-modules. Each module shows the co-occurrence between genetic (red) and pharmacological (blue) features. (c) Pathway analysis provides causal relationship based on biological knowledge in co-module features. (d) Gene signature analysis clarifies the relationship between pathway activation and sensitivity to compounds.